Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

BACKGROUND: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. Of importance to metastatic CaP, which frequently metastasises to bone, SFK are also vital to the regulation of bone remodelling. We sought t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Koreckij, T, Nguyen, H, Brown, L G, Yu, E Y, Vessella, R L, Corey, E
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2009
Teme:
Translational Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720213/
https://ncbi.nlm.nih.gov/pubmed/19603032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605178
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki